TCT 2017 | PREVAIL: Final Outcomes of the Watchman Device

Courtesy of SBHCI.

The final 5-year outcomes of the PROTECT AF and PREVAIL studies (which assessed the left atrial appendage closure device Watchman) continues to show similar stroke prevention rate to that of warfarin, though with a clear reduction in bleeding.

TCT 2017 | Resultados finales del dispositivo Watchman

The meta-analysis showed a significant reduction in hemorrhagic stroke (0.17% vs 0.87%), non-procedure related major bleeding (1.7% vs 3.6%), disabling or fatal stroke (0.37% vs 0.94%), cardiovascular death (1.3% vs 2.2%) and all-cause death (3.6% vs 4.9%). All these differences were significant.


Read also: TCT 2017 | The TRI-REPAIR and the FORMA Trials: New Devices for the “Forgotten Valve”.


As previously seen, ischemic stroke and systemic embolism rates were numerically higher with the Watchman device, though not significantly (1.6% vs 0.95%; p=0.08).

 

The 5-year outcomes of these two randomized studies show that left atrial appendage closure with this device prevents stroke in patients with non-valvular atrial fibrillation similarly to anticoagulation, in addition to minimizing major bleeding, particularly hemorrhagic stroke.


Read also: TCT 2017 | SENIOR: DES with a Bioresorbable Polymer and Short Dual Antiplatelet Therapy in Elderly Patients”.


This work, presented at TCT 2017 by Dr. Saibal Kar, was simultaneously published in the Journal of the American College of Cardiology.

 

Courtesy of SBHCI.

 

Original title: 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials.

Presenter: Kar S.

 

PREVAIL


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...